Evaluation of imidazo[2,1–b]thiazole-based anticancer agents in one decade (2011–2020): Current status and future prospects

• Published in: Bioorganic & medicinal chemistry Vol. 29; p. 115897
• Main Authors: Sbenati, Rawan M., Semreen, Mohammad H., Semreen, Ahlam M., Shehata, Mahmoud K., Alsaghir, Fai M., El-Gamal, Mohammed I.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.01.2021
• Subjects: Anticancer; Antiproliferative; Imidazo[2,1-b]thiazole; Imidazothiazole; Kinase inhibitor; Tubulin; Antiproliferative; Imidazothiazole; Tubulin; Imidazo[2,1-b]thiazole; Anticancer; Kinase inhibitor
• ISSN: 0968-0896; 1464-3391
• DOI: 10.1016/j.bmc.2020.115897

[Display omitted] •Recent reports on imidazothiazole-based anticancer agents have been reviewed.•We focused on articles published in the last decade (2011–2020).•Several imidazothiazole derivatives are kinase inhibitors.•Others are tubulin-inhibitory agents.•Miscellaneous antiproliferative imidazothiazole derivatives are also reviewed. Several reports have highlighted imidazo[2,1-b]thiazole derivatives as potential antiproliferative agents. They act through kinase inhibition, tubulin inhibition, and other molecular mechanisms of action. In the current article, we reviewed the imidazo[2,1-b]thiazole-based compounds that were reported as anticancer agents. Their biological characteristics as well as structure–activity relationship (SAR) have been reviewed and evaluated. Our main focus was on the reports published in the literature from 2011 to 2020.